Natural compound attacks HER2 positive breast cancer cells

February 18, 2014

(Medical Xpress)—A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.

The compound is called psoralen, a natural component found in foods such as figs and celery, and researchers have long understood that it that works by disrupting DNA replication and causing cell death when activated by an energy source such as UV light.

Duke researchers have now identified another way the compound works to kill , raising the potential for psoralen to be developed as an effective therapy for cancers that are particularly vulnerable to this second mode of action.

Reporting in the Feb. 14, 2014 issue of the journal PLOS ONE, the researchers detail how psoralen blocks the signaling pathway of the HER2 receptor, which is overproduced in 25 percent of breast cancers, plus ovarian, gastric and other . When HER2 is overproduced, it fuels uncontrolled cell growth, leading to an aggressive form of . Psoralen shut down this process in experiments using HER2 overexpressing cell lines.

"This was very unexpected," said senior author Neil L. Spector, M.D., the Sandra Coates Associate Professor of Medicine at Duke. "The therapy has been known to kill by causing DNA damage, but it is also having a direct anti-tumor effect on HER2 overexpressing by blocking HER2 signaling."

Psoralen also attacks another form of HER2 that is present in the nucleus of tumor cells. This form of the protein is resistant to cancer therapies such as lapatinib and trastuzumab that are otherwise effective in targeting HER2-positive cancers.

"Cancer drugs can recognize HER2 receptors when they are outside of the cell, but they don't recognize the truncated version inside the cell nucleus," Spector said. "We have shown that psoralen is effective in targeting this other form of HER2 that is resistant to current HER2-targeted therapies."

Spector said the benefits of psoralen remain dependent on its activation by an energy source, which has been an impediment to its use in solid tumors. Currently, psoralen is primarily used as a topical treatment in conjunction with UV light exposure in a process called PUVA. The treatment is used for such as psoriasis and as a therapy for lymphoma by exposing treated blood to UV radiation during a dialysis-type procedure.

"The challenge all along has been to figure out a way of generating UV light deeper in the body," Spector said. That challenge is close to being resolved. In a previous publication, Duke investigators from the Pratt School of Engineering, working in collaboration with Spector and scientists from Immunolight, the company that has funded the research, reported the development of micron-sized particles that absorb energy from X-rays to emit UV light in and around cells, much like the cathode ray tube technology used in televisions.

The tiny particles are injected into tumors along with the psoralen, then targeted by low-dose X-ray that cause the micron particles to create the UV light necessary to trigger psorlen's anti-tumor properties. Spector said the technology is being tested in animals, and may be approved for human trials as early as this year.

"A good part of four years has been trying to figure out how to overcome the biophysics challenge of generating enough energy inside the body to activate the particles and the drug," Spector said. "We've come a long way."

Explore further: Scientists propose a breast cancer drug for bladder cancer patients

Related Stories

Scientists propose a breast cancer drug for bladder cancer patients

January 22, 2014
Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and have shown that the presence of HER2 amplification ...

Study explains why drug may help more cancer patients

November 18, 2013
(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...

Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients

January 23, 2013
Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens.

Genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities

January 17, 2014
Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype ...

Enhancing the effectiveness of a breast cancer treatment

February 13, 2012
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...

PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant

December 12, 2013
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.